Cargando…

Analysis of the health product pipeline for poverty-related and neglected diseases using the Portfolio-to-Impact (P2I) modeling tool

Background: To estimate how much additional funding is needed for poverty-related and neglected disease (PRND) product development and to target new resources effectively, policymakers need updated information on the development pipeline and estimated costs to fill pipeline gaps. Methods: We previou...

Descripción completa

Detalles Bibliográficos
Autores principales: Bandara, Shashika, Chapman, Nick, Chowdhary, Vipul, Doubell, Anna, Hynen, Amelia, Rugarabamu, George, Gunn, Alexander, Yamey, Gavin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: F1000 Research Limited 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9120931/
https://www.ncbi.nlm.nih.gov/pubmed/35634166
http://dx.doi.org/10.12688/f1000research.24015.1
_version_ 1784711043972333568
author Bandara, Shashika
Chapman, Nick
Chowdhary, Vipul
Doubell, Anna
Hynen, Amelia
Rugarabamu, George
Gunn, Alexander
Yamey, Gavin
author_facet Bandara, Shashika
Chapman, Nick
Chowdhary, Vipul
Doubell, Anna
Hynen, Amelia
Rugarabamu, George
Gunn, Alexander
Yamey, Gavin
author_sort Bandara, Shashika
collection PubMed
description Background: To estimate how much additional funding is needed for poverty-related and neglected disease (PRND) product development and to target new resources effectively, policymakers need updated information on the development pipeline and estimated costs to fill pipeline gaps. Methods: We previously conducted a pipeline review to identify candidates for 35 neglected diseases as of August 31, 2017 (“2017 pipeline”). We used the Portfolio-to-Impact (P2I) tool to estimate costs to move these candidates through the pipeline, likely launches, and additional costs to develop “missing products.” We repeated this analysis, reviewing the pipeline to August 31, 2019 to get a time trend. We made a direct comparison based on the same 35 diseases (“2019 direct comparison pipeline”), then a comparison based on an expanded list of 45 diseases (“2019 complete pipeline”). Results: In the 2017 pipeline, 538 product candidates met inclusion criteria for input into the model; it would cost $16.3 billion (B) to move these through the pipeline, yielding 128 launches. In the 2019 direct comparison pipeline, we identified 690 candidates, an increase of 152 candidates from 2017; the largest increase was for Ebola.  The direct comparison 2019 pipeline yields 196 launches, costing $19.9B. In the 2019 complete pipeline, there were 754 candidates, an increase of 216 candidates from 2017, of which 152 reflected pipeline changes and 64 reflected changes in scope. The complete pipeline 2019 yields 207 launches, costing $21.0B. There would still be 16 “missing products” based on the complete 2019 pipeline; it would cost $5.5B-$14.2B (depending on product complexity) to develop these products. Conclusion: The PRNDs product development pipeline has grown by over a quarter in two years. The number of expected new product launches based on the 2019 pipeline increased by half compared to 2017; the cost of advancing the pipeline increased by a quarter.
format Online
Article
Text
id pubmed-9120931
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher F1000 Research Limited
record_format MEDLINE/PubMed
spelling pubmed-91209312022-05-27 Analysis of the health product pipeline for poverty-related and neglected diseases using the Portfolio-to-Impact (P2I) modeling tool Bandara, Shashika Chapman, Nick Chowdhary, Vipul Doubell, Anna Hynen, Amelia Rugarabamu, George Gunn, Alexander Yamey, Gavin F1000Res Research Article Background: To estimate how much additional funding is needed for poverty-related and neglected disease (PRND) product development and to target new resources effectively, policymakers need updated information on the development pipeline and estimated costs to fill pipeline gaps. Methods: We previously conducted a pipeline review to identify candidates for 35 neglected diseases as of August 31, 2017 (“2017 pipeline”). We used the Portfolio-to-Impact (P2I) tool to estimate costs to move these candidates through the pipeline, likely launches, and additional costs to develop “missing products.” We repeated this analysis, reviewing the pipeline to August 31, 2019 to get a time trend. We made a direct comparison based on the same 35 diseases (“2019 direct comparison pipeline”), then a comparison based on an expanded list of 45 diseases (“2019 complete pipeline”). Results: In the 2017 pipeline, 538 product candidates met inclusion criteria for input into the model; it would cost $16.3 billion (B) to move these through the pipeline, yielding 128 launches. In the 2019 direct comparison pipeline, we identified 690 candidates, an increase of 152 candidates from 2017; the largest increase was for Ebola.  The direct comparison 2019 pipeline yields 196 launches, costing $19.9B. In the 2019 complete pipeline, there were 754 candidates, an increase of 216 candidates from 2017, of which 152 reflected pipeline changes and 64 reflected changes in scope. The complete pipeline 2019 yields 207 launches, costing $21.0B. There would still be 16 “missing products” based on the complete 2019 pipeline; it would cost $5.5B-$14.2B (depending on product complexity) to develop these products. Conclusion: The PRNDs product development pipeline has grown by over a quarter in two years. The number of expected new product launches based on the 2019 pipeline increased by half compared to 2017; the cost of advancing the pipeline increased by a quarter. F1000 Research Limited 2020-05-21 /pmc/articles/PMC9120931/ /pubmed/35634166 http://dx.doi.org/10.12688/f1000research.24015.1 Text en Copyright: © 2020 Bandara S et al. https://creativecommons.org/licenses/by/3.0/igo/This is an open access article distributed under the terms of the Creative Commons Attribution IGO Licence.
spellingShingle Research Article
Bandara, Shashika
Chapman, Nick
Chowdhary, Vipul
Doubell, Anna
Hynen, Amelia
Rugarabamu, George
Gunn, Alexander
Yamey, Gavin
Analysis of the health product pipeline for poverty-related and neglected diseases using the Portfolio-to-Impact (P2I) modeling tool
title Analysis of the health product pipeline for poverty-related and neglected diseases using the Portfolio-to-Impact (P2I) modeling tool
title_full Analysis of the health product pipeline for poverty-related and neglected diseases using the Portfolio-to-Impact (P2I) modeling tool
title_fullStr Analysis of the health product pipeline for poverty-related and neglected diseases using the Portfolio-to-Impact (P2I) modeling tool
title_full_unstemmed Analysis of the health product pipeline for poverty-related and neglected diseases using the Portfolio-to-Impact (P2I) modeling tool
title_short Analysis of the health product pipeline for poverty-related and neglected diseases using the Portfolio-to-Impact (P2I) modeling tool
title_sort analysis of the health product pipeline for poverty-related and neglected diseases using the portfolio-to-impact (p2i) modeling tool
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9120931/
https://www.ncbi.nlm.nih.gov/pubmed/35634166
http://dx.doi.org/10.12688/f1000research.24015.1
work_keys_str_mv AT bandarashashika analysisofthehealthproductpipelineforpovertyrelatedandneglecteddiseasesusingtheportfoliotoimpactp2imodelingtool
AT chapmannick analysisofthehealthproductpipelineforpovertyrelatedandneglecteddiseasesusingtheportfoliotoimpactp2imodelingtool
AT chowdharyvipul analysisofthehealthproductpipelineforpovertyrelatedandneglecteddiseasesusingtheportfoliotoimpactp2imodelingtool
AT doubellanna analysisofthehealthproductpipelineforpovertyrelatedandneglecteddiseasesusingtheportfoliotoimpactp2imodelingtool
AT hynenamelia analysisofthehealthproductpipelineforpovertyrelatedandneglecteddiseasesusingtheportfoliotoimpactp2imodelingtool
AT rugarabamugeorge analysisofthehealthproductpipelineforpovertyrelatedandneglecteddiseasesusingtheportfoliotoimpactp2imodelingtool
AT gunnalexander analysisofthehealthproductpipelineforpovertyrelatedandneglecteddiseasesusingtheportfoliotoimpactp2imodelingtool
AT yameygavin analysisofthehealthproductpipelineforpovertyrelatedandneglecteddiseasesusingtheportfoliotoimpactp2imodelingtool